Future Fertility unveils ROSE™, a new AI-based egg quality tool that aims to transform donor egg programs

As demand for egg donation grows around the world, Future Fertility is bringing transparency, predictability, and reliability to donor oocyte programs.

The company has announced the launch of ROSE—a new AI-powered oocyte quality workflow and report built specifically for egg banks and donor egg programs.

Jullin Fjeldstad is Head of Clinical Embryology and Scientific Operations at Future Fertility.

Fjeldstad said: “Egg banks have historically lacked tools to assess and manage donor oocyte quality in an objective way.

“ROSE™ brings standardisation into the equation, offering new AI-based insights and a workflow solution that optimise how donor eggs are managed, grouped, and allocated.”

With the number of IVF cycles involving donor eggs increasing globally, clinics and egg banks face rising pressure to deliver quality assurance in donor oocyte distribution.

Experts estimate that donor eggs are used in approximately 10 per cent of all cycles.

Meanwhile, the global donor egg IVF market is projected to reach $6.6 billion by 2032, up from $2.3 billion in 2022.

ROSE provides egg banks with a clinically validated, AI-powered tool that predicts the likelihood of each oocyte developing into a high-quality embryo (blastocyst).

Powered by the world’s largest dataset of oocyte images and associated reproductive outcomes, ROSE has been clinically validated for use with donor egg populations— enabling egg banks to:

• Optimise oocyte distribution by expected blastocyst outcomes
• Provide objective quality assurance for donor oocyte groupings
• Track and manage donor cycles and oocyte inventory with an AI-based tool and custom workflow solution
• Build trust with receiving clinics through intuitive, image-based reports

ROSE was developed in consultation with real egg bank partners who helped define requirements and refine the platform’s capabilities.

Dr. Catello Scarica, Scientific director at New Fertility Group, noted: “We’ve been impressed by how the ROSE tool supports quality control and decision-making in our donor cycles. It gives our team greater confidence in the eggs we distribute and enables better alignment with receiving clinics.”

WeBank’s Development Director, Dr Natalia Basile added: “ROSE is transforming how we manage donor eggs.

“The objective scores, traceability, and reporting help us organise inventory and reduce uncertainty—especially valuable when outcomes don’t meet expectations.”

From a clinical workflow perspective, the platform is designed for seamless integration. ROSE connects directly with microscopes and laser systems, allowing egg banks to capture 2D oocyte images in real time and securely upload them to the cloud.

Within minutes, the AI model—proven to be more accurate than embryologists in multiple studies—delivers predictions about blastocyst potential, with a workflow solution that manages, tracks and optimises groupings of oocytes for distribution.

Dr Danilo Cimadomo is Global Manager of AI and Data Management for Embryological Research at IVIRMA Global Research Alliance.

Cimadomo  said: “The future of egg donation lies in complementing information about egg quantity with eggs’ blastulation potential to personalise the number of oocytes allocated per recipient.

“Tools like ROSE, can help maximise success while minimising the number of surplus embryos by matching patients with an ideal number of high-quality eggs based on their unique profile.”

Rafael Gonzalez, Global Head of Sales and Commercial Strategy at Future Fertility, added: “Clinics are asking for greater confidence when it comes to donor egg quality, both recipient clinics and donor egg banks.

“ROSE provides a scalable, data-driven way to meet that demand—giving both donor labs and recipient clinics a shared, objective language to talk about egg quality.”